# OnCo record nct07221734 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07221734/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07221734", "NCT07221734" ;
  schema:name "Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma"@en ;
  schema:alternateName "LEON"@en ;
  schema:description "A phase 3 trial of Nivolumab in melanoma, run by mAbxience Research S.L., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07221734/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07221734> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-12-29" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/mabxience-research-s-l/> .